SWS Medical(SH:688410)2025-01-19 08:25Financial Performance Forecast - The company expects a net profit attributable to shareholders of the parent company for 2024 to be between 70 million and 80 million yuan, representing a decrease of 58.87% to 64.01% compared to the previous year[3]. - The net profit excluding non-recurring gains and losses is projected to be between 60 million and 70 million yuan, reflecting a decline of 60.25% to 65.93% year-on-year[4]. - In the previous year, the total profit was 219.95 million yuan, with a net profit attributable to shareholders of 194.50 million yuan[5]. - The performance forecast is based on preliminary estimates and has not yet been audited by registered accountants[7]. - Investors are advised to pay attention to investment risks as the forecast data is preliminary and subject to change upon the release of the audited annual report[8]. Revenue and Market Strategy - The company anticipates an increase in operating revenue for 2024, excluding the impact of high sales from CRRT devices in 2023[6]. - The company is implementing a "domestic + international" dual-drive strategy, with significant improvements in market share for blood dialysis machines, ranking first in procurement quantity in Q3 2024[6]. - The company is strengthening its international marketing team and expects overseas revenue to increase in 2024[6]. Research and Development - R&D investment for 2024 is expected to significantly increase compared to the previous year, which may impact net profit in the short term but will enhance long-term competitiveness[6].